Cicada fungus medicine for ALS patients with high sphingolipids
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a traditional Chinese medicine made from cicada fungus for people with ALS who also have high levels of certain fats in their blood. The goal is to see if it can slow the disease and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ALS.
- Your blood tests show higher than normal levels of certain fats called sphingolipids.
- Your ALS symptoms started within the last 2 years.
- You are between 18 and 80 years old.
- If you take riluzole or edaravone, your dose has been the same for at least 30 days.
- You are not pregnant or breastfeeding, and you can swallow oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called cyclophosphamide can slow the progression of ALS. It's given to people who have had symptoms for less than 2 years and still have good breathing, to see if calming the immune system can help protect nerve cells.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.